Cover Image
Market Research Report

Generics Top 5 Emerging Markets Industry Guide 2013-2022

Published by MarketLine Product code 353043
Published Content info 132 Pages
Delivery time: 1-2 business days
Price
Back to Top
Generics Top 5 Emerging Markets Industry Guide 2013-2022
Published: October 25, 2018 Content info: 132 Pages
Description

Summary

The Emerging 5 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Questions Answered:

What was the size of the emerging five generics market by value in 2017?

What will be the size of the emerging five generics market in 2022?

What factors are affecting the strength of competition in the emerging five generics market?

How has the market performed over the last five years?

How large is the emerging five generics market in relation to its regional counterparts?

Scope

  • Essential resource for top-line data and analysis covering the emerging five generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
  • These countries contributed $88,890.2 million to the global generics industry in 2017, with a compound annual growth rate (CAGR) of 11% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $1,26,524.6 million in 2022, with a CAGR of 7.3% over the 2017-22 period.
  • Within the generics industry, China is the leading country among the top 5 emerging nations, with market revenues of $61,399.8 million in 2017. This was followed by India and Brazil with a value of $14,395.1 and $6,435.8 million, respectively.
  • China is expected to lead the generics industry in the top five emerging nations, with a value of $86,778.1 million in 2022, followed by India and Brazil with expected values of $20,551.5 and $9,201.9 million, respectively.
  • Reasons to buy
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging five generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging five generics market
  • Leading company profiles reveal details of key generics market players' emerging five operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the emerging five generics market with five year forecasts by both value and volume
  • Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country
Table of Contents
Product Code: MLIG180057-05

Table of Contents

Introduction 11

  • What is this report about? 11
  • Who is the target reader? 11
  • How to use this report 11
  • Definitions 11

Top 5 Emerging Countries Generics 12

  • Industry Outlook 12

Generics in South Africa 15

  • Market Overview 15
  • Market Data 16
  • Market Segmentation 18
  • Market outlook 19
  • Five forces analysis 21
  • Macroeconomic indicators 27

Generics in Brazil 29

  • Market Overview 29
  • Market Data 30
  • Market Segmentation 32
  • Market outlook 33
  • Five forces analysis 35
  • Macroeconomic indicators 41

Generics in China 43

  • Market Overview 43
  • Market Data 44
  • Market Segmentation 46
  • Market outlook 47
  • Five forces analysis 49
  • Macroeconomic indicators 56

Generics in India 58

  • Market Overview 58
  • Market Data 59
  • Market Segmentation 61
  • Market outlook 62
  • Five forces analysis 64
  • Macroeconomic indicators 70

Generics in Mexico 72

  • Market Overview 72
  • Market Data 73
  • Market Segmentation 75
  • Market outlook 76
  • Five forces analysis 78
  • Macroeconomic indicators 84

Company Profiles 86

  • Leading Companies 86

Appendix 130

  • Methodology 130
  • About MarketLine 131

List of Tables

  • Table 1: Top 5 emerging countries generics industry, revenue ($m), 2013-22
  • Table 2: Top 5 emerging countries generics industry, revenue ($m), 2013-17
  • Table 3: Top 5 emerging countries generics industry forecast, revenue ($m), 2017-22
  • Table 4: South Africa generics market value: $ million, 2013-17
  • Table 5: South Africa generics market volume: % of total pharma, 2013-17
  • Table 6: South Africa generics market geography segmentation: $ million, 2017
  • Table 7: South Africa generics market value forecast: $ million, 2017-22
  • Table 8: South Africa generics market volume forecast: % of total pharma, 2017-22
  • Table 9: South Africa size of population (million), 2013-17
  • Table 10: South Africa gdp (constant 2005 prices, $ billion), 2013-17
  • Table 11: South Africa gdp (current prices, $ billion), 2013-17
  • Table 12: South Africa inflation, 2013-17
  • Table 13: South Africa consumer price index (absolute), 2013-17
  • Table 14: South Africa exchange rate, 2013-17
  • Table 15: Brazil generics market value: $ million, 2013-17
  • Table 16: Brazil generics market volume: % of total pharma, 2013-17
  • Table 17: Brazil generics market geography segmentation: $ million, 2017
  • Table 18: Brazil generics market value forecast: $ million, 2017-22
  • Table 19: Brazil generics market volume forecast: % of total pharma, 2017-22
  • Table 20: Brazil size of population (million), 2013-17
  • Table 21: Brazil gdp (constant 2005 prices, $ billion), 2013-17
  • Table 22: Brazil gdp (current prices, $ billion), 2013-17
  • Table 23: Brazil inflation, 2013-17
  • Table 24: Brazil consumer price index (absolute), 2013-17
  • Table 25: Brazil exchange rate, 2013-17
  • Table 26: China generics market value: $ billion, 2013-17
  • Table 27: China generics market volume: % of total pharma, 2013-17
  • Table 28: China generics market geography segmentation: $ billion, 2017
  • Table 29: China generics market value forecast: $ billion, 2017-22
  • Table 30: China generics market volume forecast: % of total pharma, 2017-22
  • Table 31: China size of population (million), 2013-17
  • Table 32: China gdp (constant 2005 prices, $ billion), 2013-17
  • Table 33: China gdp (current prices, $ billion), 2013-17
  • Table 34: China inflation, 2013-17
  • Table 35: China consumer price index (absolute), 2013-17
  • Table 36: China exchange rate, 2013-17
  • Table 37: India generics market value: $ million, 2013-17
  • Table 38: India generics market volume: % of total pharma, 2013-17
  • Table 39: India generics market geography segmentation: $ million, 2017
  • Table 40: India generics market value forecast: $ million, 2017-22
  • Table 41: India generics market volume forecast: % of total pharma, 2017-22
  • Table 42: India size of population (million), 2013-17
  • Table 43: India gdp (constant 2005 prices, $ billion), 2013-17
  • Table 44: India gdp (current prices, $ billion), 2013-17
  • Table 45: India inflation, 2013-17
  • Table 46: India consumer price index (absolute), 2013-17
  • Table 47: India exchange rate, 2013-17
  • Table 48: Mexico generics market value: $ million, 2013-17
  • Table 49: Mexico generics market volume: % of total pharma, 2013-17
  • Table 50: Mexico generics market geography segmentation: $ million, 2017
  • Table 51: Mexico generics market value forecast: $ million, 2017-22
  • Table 52: Mexico generics market volume forecast: % of total pharma, 2017-22
  • Table 53: Mexico size of population (million), 2013-17
  • Table 54: Mexico gdp (constant 2005 prices, $ billion), 2013-17
  • Table 55: Mexico gdp (current prices, $ billion), 2013-17
  • Table 56: Mexico inflation, 2013-17
  • Table 57: Mexico consumer price index (absolute), 2013-17
  • Table 58: Mexico exchange rate, 2013-17
  • Table 59: Adcock Ingram: key facts
  • Table 60: Adcock Ingram: key financials ($)
  • Table 61: Adcock Ingram: key financials (ZAR)
  • Table 62: Adcock Ingram: key financial ratios
  • Table 63: Aspen Pharmacare Holdings Ltd: key facts
  • Table 64: Aspen Pharmacare Holdings Ltd: key financials ($)
  • Table 65: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
  • Table 66: Aspen Pharmacare Holdings Ltd: key financial ratios
  • Table 67: Novartis AG: key facts
  • Table 68: Novartis AG: key financials ($)
  • Table 69: Novartis AG: key financial ratios
  • Table 70: Ache Laboratorios Farmaceuticos SA: key facts
  • Table 71: EMS SA: key facts
  • Table 72: Eurofarma Laboratorios SA: key facts
  • Table 73: Sanofi SA: key facts
  • Table 74: Sanofi SA: key financials ($)
  • Table 75: Sanofi SA: key financials (€)
  • Table 76: Sanofi SA: key financial ratios
  • Table 77: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
  • Table 78: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
  • Table 79: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
  • Table 80: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
  • Table 81: Mylan N.V.: key facts
  • Table 82: Mylan N.V.: key financials ($)
  • Table 83: Mylan N.V.: key financial ratios
  • Table 84: Aurobindo Pharma Limited: key facts
  • Table 85: Aurobindo Pharma Limited: key financials ($)
  • Table 86: Aurobindo Pharma Limited: key financials (Rs.)
  • Table 87: Aurobindo Pharma Limited: key financial ratios
  • Table 88: Cipla Limited: key facts
  • Table 89: Cipla Limited: key financials ($)
  • Table 90: Cipla Limited: key financials (Rs.)
  • Table 91: Cipla Limited: key financial ratios
  • Table 92: Lupin Ltd: key facts
  • Table 93: Lupin Ltd: key financials ($)
  • Table 94: Lupin Ltd: key financials (Rs.)
  • Table 95: Lupin Ltd: key financial ratios
  • Table 96: Sun Pharmaceutical Industries Ltd: key facts
  • Table 97: Sun Pharmaceutical Industries Ltd: key financials ($)
  • Table 98: Sun Pharmaceutical Industries Ltd: key financials (Rs.)
  • Table 99: Sun Pharmaceutical Industries Ltd: key financial ratios
  • Table 100: Apotex, Inc.: key facts
  • Table 101: Pfizer Inc.: key facts
  • Table 102: Pfizer Inc.: key financials ($)
  • Table 103: Pfizer Inc.: key financial ratios
  • Table 104: Teva Pharmaceutical Industries Limited: key facts
  • Table 105: Teva Pharmaceutical Industries Limited: key financials ($)
  • Table 106: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures

  • Figure 1: Top 5 emerging countries generics industry, revenue ($m), 2013-22
  • Figure 2: Top 5 emerging countries generics industry, revenue ($m), 2013-17
  • Figure 3: Top 5 emerging countries generics industry forecast, revenue ($m), 2017-22
  • Figure 4: South Africa generics market value: $ million, 2013-17
  • Figure 5: South Africa generics market volume: % of total pharma, 2013-17
  • Figure 6: South Africa generics market geography segmentation: % share, by value, 2017
  • Figure 7: South Africa generics market value forecast: $ million, 2017-22
  • Figure 8: South Africa generics market volume forecast: % of total pharma, 2017-22
  • Figure 9: Forces driving competition in the generics market in South Africa, 2017
  • Figure 10: Drivers of buyer power in the generics market in South Africa, 2017
  • Figure 11: Drivers of supplier power in the generics market in South Africa, 2017
  • Figure 12: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2017
  • Figure 13: Factors influencing the threat of substitutes in the generics market in South Africa, 2017
  • Figure 14: Drivers of degree of rivalry in the generics market in South Africa, 2017
  • Figure 15: Brazil generics market value: $ million, 2013-17
  • Figure 16: Brazil generics market volume: % of total pharma, 2013-17
  • Figure 17: Brazil generics market geography segmentation: % share, by value, 2017
  • Figure 18: Brazil generics market value forecast: $ million, 2017-22
  • Figure 19: Brazil generics market volume forecast: % of total pharma, 2017-22
  • Figure 20: Forces driving competition in the generics market in Brazil, 2017
  • Figure 21: Drivers of buyer power in the generics market in Brazil, 2017
  • Figure 22: Drivers of supplier power in the generics market in Brazil, 2017
  • Figure 23: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2017
  • Figure 24: Factors influencing the threat of substitutes in the generics market in Brazil, 2017
  • Figure 25: Drivers of degree of rivalry in the generics market in Brazil, 2017
  • Figure 26: China generics market value: $ billion, 2013-17
  • Figure 27: China generics market volume: % of total pharma, 2013-17
  • Figure 28: China generics market geography segmentation: % share, by value, 2017
  • Figure 29: China generics market value forecast: $ billion, 2017-22
  • Figure 30: China generics market volume forecast: % of total pharma, 2017-22
  • Figure 31: Forces driving competition in the generics market in China, 2017
  • Figure 32: Drivers of buyer power in the generics market in China, 2017
  • Figure 33: Drivers of supplier power in the generics market in China, 2017
  • Figure 34: Factors influencing the likelihood of new entrants in the generics market in China, 2017
  • Figure 35: Factors influencing the threat of substitutes in the generics market in China, 2017
  • Figure 36: Drivers of degree of rivalry in the generics market in China, 2017
  • Figure 37: India generics market value: $ million, 2013-17
  • Figure 38: India generics market volume: % of total pharma, 2013-17
  • Figure 39: India generics market geography segmentation: % share, by value, 2017
  • Figure 40: India generics market value forecast: $ million, 2017-22
  • Figure 41: India generics market volume forecast: % of total pharma, 2017-22
  • Figure 42: Forces driving competition in the generics market in India, 2017
  • Figure 43: Drivers of buyer power in the generics market in India, 2017
  • Figure 44: Drivers of supplier power in the generics market in India, 2017
  • Figure 45: Factors influencing the likelihood of new entrants in the generics market in India, 2017
  • Figure 46: Factors influencing the threat of substitutes in the generics market in India, 2017
  • Figure 47: Drivers of degree of rivalry in the generics market in India, 2017
  • Figure 48: Mexico generics market value: $ million, 2013-17
  • Figure 49: Mexico generics market volume: % of total pharma, 2013-17
  • Figure 50: Mexico generics market geography segmentation: % share, by value, 2017
  • Figure 51: Mexico generics market value forecast: $ million, 2017-22
  • Figure 52: Mexico generics market volume forecast: % of total pharma, 2017-22
  • Figure 53: Forces driving competition in the generics market in Mexico, 2017
  • Figure 54: Drivers of buyer power in the generics market in Mexico, 2017
  • Figure 55: Drivers of supplier power in the generics market in Mexico, 2017
  • Figure 56: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2017
  • Figure 57: Factors influencing the threat of substitutes in the generics market in Mexico, 2017
  • Figure 58: Drivers of degree of rivalry in the generics market in Mexico, 2017
  • Figure 59: Adcock Ingram: revenues & profitability
  • Figure 60: Adcock Ingram: assets & liabilities
  • Figure 61: Aspen Pharmacare Holdings Ltd: revenues & profitability
  • Figure 62: Aspen Pharmacare Holdings Ltd: assets & liabilities
  • Figure 63: Novartis AG: revenues & profitability
  • Figure 64: Novartis AG: assets & liabilities
  • Figure 65: Sanofi SA: revenues & profitability
  • Figure 66: Sanofi SA: assets & liabilities
  • Figure 67: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
  • Figure 68: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
  • Figure 69: Mylan N.V.: revenues & profitability
  • Figure 70: Mylan N.V.: assets & liabilities
  • Figure 71: Aurobindo Pharma Limited: revenues & profitability
  • Figure 72: Aurobindo Pharma Limited: assets & liabilities
  • Figure 73: Cipla Limited: revenues & profitability
  • Figure 74: Cipla Limited: assets & liabilities
  • Figure 75: Lupin Ltd: revenues & profitability
  • Figure 76: Lupin Ltd: assets & liabilities
  • Figure 77: Sun Pharmaceutical Industries Ltd: revenues & profitability
  • Figure 78: Sun Pharmaceutical Industries Ltd: assets & liabilities
  • Figure 79: Pfizer Inc.: revenues & profitability
  • Figure 80: Pfizer Inc.: assets & liabilities
  • Figure 81: Teva Pharmaceutical Industries Limited: revenues & profitability
  • Figure 82: Teva Pharmaceutical Industries Limited: assets & liabilities
Back to Top